FDA Declares Mouth-Cooling Gadget Officially Cool
Published Date: 6/1/2026
Rule
Summary
The FDA is officially putting the intraoral cooling device into class II, meaning it has special safety rules but fewer hurdles than the highest-risk devices. This change helps make sure the device is safe and effective while making it easier for patients to get this cool tech. The new classification is effective June 1, 2026, but it’s been in place since October 14, 2022, so manufacturers can plan ahead without extra costs.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Device moved to Class II (special controls)
The FDA officially classified the intraoral cooling device into class II (special controls) effective June 1, 2026, with the classification applicable on October 14, 2022. FDA says this classification will provide reasonable assurance of safety and effectiveness and will enhance patients' access in part by reducing regulatory burdens.
Required safety and testing controls
Manufacturers must meet special controls: non-clinical performance testing (including thermal testing for cooling consistency and material integrity), electromagnetic compatibility and electrical safety testing, software verification/validation and hazard analysis for software components, biocompatibility of patient-contacting parts, and labeling that includes temperature cooling range, duration of cooling, and stop-use instructions.
Subject to 510(k) premarket notification
FDA states that intraoral cooling devices are subject to premarket notification requirements under section 510(k) of the FD&C Act and FDA has not determined the device type should be exempt under section 510(m).
Creates a predicate for future devices
Because FDA classified the device via the De Novo process, the intraoral cooling device can serve as a predicate for future devices of that type, allowing other sponsors to use the less burdensome 510(k) process to market substantially equivalent devices.
Device is prescription-only
The intraoral cooling device is identified as a prescription use device intended to cool the mouth to reduce the likelihood of oral mucositis. As a prescription device, it is subject to the prescription-device labeling rules referenced in the order.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17659, Rahim Shafa; Denial of Hearing; Final Debarment Order
The Food and Drug Administration (FDA or Agency) is denying a request for a hearing submitted by Rahim Shafa (Dr. Shafa) and is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Dr. Shafa from providing services in any capacity to a person that has an approved or pending drug product application and debarring Dr. Shafa for 20 years from importing or offering for import any drug into the United States. FDA bases this order on the findings that Dr. Shafa was convicted of multiple felonies under Federal law that relate to the regulation of any drug product under the FD&C Act and the importation into the United States of any drug or controlled substance under the FD&C Act. FDA provided notice to Dr. Shafa of the proposed debarment and an opportunity to request a hearing. Dr. Shafa submitted a request for a hearing but failed to file with the Agency information and analyses sufficient to create a basis for a hearing.
2026-17676, Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act and Associated Fees
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection pertaining to the registration of human drug compounding outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and associated fees.
2026-17598, Agency Information Collection Activities; Proposed Collection; Comment Request; Focus Groups and Interviews as Used by the Food and Drug Administration
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the generic collection of focus group information as used by FDA for all FDA-regulated products.
Previous / Next Documents
Previous: 2026-10898, Medical Devices; Hematology and Pathology Devices; Classification of the Von Willebrand Factor Assay
The FDA is officially putting the von Willebrand factor assay into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps labs and patients get access to this important blood test faster and safer, starting June 1, 2026. If you make or use these devices, expect smoother approvals and no big cost jumps.
Next: 2026-10904, Medical Devices; Gastroenterology-Urology Devices; Classification of the Orally Ingested Transient Device for Constipation
The FDA is officially putting the new swallowed device for constipation into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this cool innovation by cutting down red tape. The new rules took effect June 1, 2026, and could save companies time and money getting their devices approved.